REFERENCES
- Meynard JL, Guiguet M, Arsac S, Frottier J, Meyohas MC. Frequency and risk factors of infectious complications in neutropenic patients infected with HIV. AIDS. 1997;11:995–998.
- Levine AM, Karim R, Mack W, et al. Neutropenia in human immunodeficiency virus infection: data from the women's interagency HIV study. Arch Intern Med. 2006;166:405–410.
- Armstrong WS, Kazanjian P. Use of cytokines in human immunodeficiency virus-infected patients: colony-stimulat-ing factors, erythropoietin, and interleukin-2. Clin Infect Dis. 2001;32:766–773.
- Tien PC. Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office. Am J Gastroenterol. 2005;100:2338–2354.
- Col!antes RS, Younossi ZM. The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. J Clin Gastroenterol. 2005;39:S9–13.
- Cooper CL, Al-Bedwawi S, Lee C, Garber G. Rate of infec-tious complications during interferon-based therapy for hepatitis C is not related to neutropenia. Clin Infect Dis. 2006;42:1674–1678.
- Soza A, Everhard JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology. 2002:1273–1279.
- Puoti M, Babudieri S, Rezza G, et al. Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? Antivir Ther. 2004;9:627–630.
- Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, and Infectious Diseases Society of America, and the Ameri-can Society of Blood and Marrow. Transplantation. 2000;49:RR–10.